Takara BioFRA:TF2 74 Dividend Payout Ratio is 0.00 as of Mar. 2026. GuruFocus rates FRA:TF2 with a GF Score™ of 74/100 and a GF Value™ of €4.46 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 134 Biotechnology companies, Takara Bio ranks worse than 746267.91% on this metric.
The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period. Takara Bio's Dividend Payout Ratio for the
months ended in Mar. 2026 was 0.00.
The historical rank and industry rank for Takara Bio's Dividend Payout Ratio or its related term are showing as below:
During the past 13 years, the highest Dividend Payout Ratio of Takara Bio was 1.37. The lowest was 0.11. And the median was 0.22.
FRA:TF2's Dividend Payout Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 0.445 * Ranked among companies with meaningful Dividend Payout Ratio only.
During the past 12 months, Takara Bio's average Dividends Per Share Growth Rate was -100.00% per year.
During the past 13 years, the highest 3-Year average Dividends Per Share Growth Rate of Takara Bio was 73.80% per year. The lowest was -19.80% per year. And the median was 26.00% per year.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.
Takara Bio (FRA:TF2) Dividend Payout Ratio Explanation
In dividends investing, Dividend Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Takara Bio Dividend Payout Ratio Related Terms
Takara Bio Dividend Payout Ratio Historical Data
* Premium members only.
The historical data trend for Takara Bio's Dividend Payout Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:TF2 vs VRTX, REGN, ALNY: Dividend Payout Ratio Comparison
For the Biotechnology subindustry, Takara Bio's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Takara Bio Dividend Payout Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Takara Bio's Dividend Payout Ratio distribution charts can be found below:
* The bar in red indicates where Takara Bio's Dividend Payout Ratio falls into.
The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period.
Takara Bio's Dividend Payout Ratio for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Takara Bio (FRA:TF2) has a Dividend Payout Ratio of 0.00 as of Mar. 2026. Dividend payout ratio is the percent of company earnings paid out as dividends. View historical data on Takara Bio and its competitors. Over the past decade, Takara Bio's Dividend Payout Ratio has ranged from 0.11 to 1.37. According to the industry distribution chart, Takara Bio ranks #999999 out of 134 companies in the Biotechnology industry.
Is Takara Bio's Dividend Payout Ratio too high?
Takara Bio's current Dividend Payout Ratio is 0.00. Over the past 10 years, this metric has ranged from a low of 0.11 to a high of 1.37. Based on the distribution chart, Takara Bio ranks #999999 out of 134 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Takara Bio has a GF Score™ of 74/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Takara Bio's Dividend Payout Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Takara Bio ranks #999999 out of 134 companies for Dividend Payout Ratio. This places Takara Bio in the lower half of its industry. The industry median Dividend Payout Ratio is 0.45. Historically, Takara Bio's own Dividend Payout Ratio has ranged from 0.11 to 1.37 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Payout Ratio for a Biotechnology company?
The median Dividend Payout Ratio among Biotechnology companies is 0.45, based on 134 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Payout Ratio significantly above this median, while those in the bottom quartile fall well below. However, Dividend Payout Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Payout Ratio mean?
A high Dividend Payout Ratio can signal that a stock is expensive relative to its fundamentals. Dividend payout ratio is the percent of company earnings paid out as dividends. View historical data on Takara Bio and its competitors. For the Biotechnology industry, the median Dividend Payout Ratio is 0.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Takara Bio's current Dividend Payout Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Takara Bio stock overvalued right now?
Based on GuruFocus' analysis, Takara Bio (FRA:TF2) is currently considered Significantly Overvalued. The stock's GF Value™ is €4.46, compared to a current price of €5.95 — trading 33.4% above its estimated fair value. The current Dividend Payout Ratio is 0.00. Takara Bio's overall GF Score™ is 74/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Payout Ratio calculated?
Dividend Payout Ratio is calculated from a company's financial statements. For Takara Bio (FRA:TF2), the current Dividend Payout Ratio is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Takara Bio (FRA:TF2) Overvalued in 2026?
Based on GuruFocus' analysis, Takara Bio stock appears to be overvalued.
The current stock price of €5.95 is trading 33.4% above its estimated GF Value™ of €4.46.
GuruFocus considers Takara Bio to be Significantly Overvalued.
Key valuation signals for FRA:TF2:
Dividend Payout Ratio: 0.00
GF Value™: €4.46 vs. price of €5.95 (33.4% above fair value)
No single metric tells the full story. See the FRA:TF2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Takara Bio Inc is a biotechnology company that develops gene therapy procedures. The company reports in three business segments: Bioindustry, Gene therapy, and AgriBio. Takara's bioindustry business provides research reagents, scientific instruments, and various contracted services to universities and companies around the world. The company's gene therapy business is focused on treating cancer and HIV. Its AgriBio business aims to leverage biotechnologies in the food ingredient field, including large-scale mushroom production. The vast majority of Takara's revenue is derived from its bioindustry segment.
74GF Score
Get the complete analysis for FRA:TF2
Dividend Payout Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:TF2 has been successfully added to your 
